IntelliPharmaCeutics International (IntelliPharmaCeutics International) EV-to-EBIT : -1.30 (As of Apr. 25, 2024)

IntelliPharmaCeutics International EV-to-EBIT Chart

IntelliPharmaCeutics International Annual Data
	Trend	Nov13	Nov14	Nov15	Nov16	Nov17	Nov18	Nov19	Nov20	Nov21	Nov22
EV-to-EBIT		Get a 7-Day Free Trial					-0.10	-0.66	-2.01	-1.05	-1.81

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
EV-to-EBIT	Get a 7-Day Free Trial															-1.35	-1.81	-1.96	-2.93	-1.44

Competitive Comparison of IntelliPharmaCeutics International's EV-to-EBIT

For the Biotechnology subindustry, IntelliPharmaCeutics International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IntelliPharmaCeutics International's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's EV-to-EBIT falls into.

IntelliPharmaCeutics International EV-to-EBIT Calculation

IntelliPharmaCeutics International's EV-to-EBIT for today is calculated as:

IntelliPharmaCeutics International's current Enterprise Value is $3.76 Mil.
IntelliPharmaCeutics International's EBIT for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IntelliPharmaCeutics International  (OTCPK:IPCIF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

IntelliPharmaCeutics International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Aug. 2023 is calculated as:

IntelliPharmaCeutics International's Enterprise Value for the quarter that ended in Aug. 2023 was $4.43 Mil.
IntelliPharmaCeutics International's EBIT for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IntelliPharmaCeutics International EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description